1. X
  2. Michael Hofman
Log inSign up
Michael Hofman
2,650 posts
Image
user avatar
Michael Hofman
@DrMHofman
Working together to improve patient outcomes with personalised medicine & precision oncology: theranostics. PET/CT, prostate cancer ☢️ Prof 🇦🇺
Melbourne, Victoria
petermac.org/prostic
Joined December 2013
476
Following
6,074
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • user avatar
    Michael Hofman
    @DrMHofman
    Apr 13, 2024
    ENZA-P in @TheLancetOncol Lu-177 PSMA-617 + enzalutamide vs. enza alone: ● ↑PFS: 13.0 vs 7.8, hazard radio 0.43 ● PSA90 response 78% vs 37% ● PSA50 response 93% vs. 68% ● no additional side effects Incredible work from @drlouiseemmett @Prof_IanD & @ANZUPtrials team
    Image
    Image
    Image
    21K021K
  • user avatar
    Michael Hofman
    @DrMHofman
    Feb 24, 2023
    Another extraordinary day at @PeterMacCC. We gave cycle #17 of Lu-177 PSMA-617 to a patient with prostate cancer. Continues to benefit 4+ years. Bloods and renal function normal. Even more extraordinary, We were both wearing the same socks. @pros_tic
    Image
    18K018K
  • user avatar
    Michael Hofman
    @DrMHofman
    Feb 18, 2023
    Reading the NCCN v1.2023 prostate cancer guidelines and noting this change of wording: "Ga-68 PSMA-11 or F-18 piflufolastat PSMA PET/CT or PET/MRI are preferred for bone and soft tissue (full body) imaging.". No longer an "alternative". Now preferred.
    Image
    20K020K
  • user avatar
    Michael Hofman
    @DrMHofman
    Mar 10, 2023
    1/ #LuTectomy #EAU23 Game Changing Session: first use of Lu-177 PSMA-617 first-line in patients with high-risk localised N0/N1 prostate cancer: 20pt. 1-2 cycles→prostatectomy. ☢36Gy. 45% PSA50-RR. Safe. Few toxicities. @RenuEapen @declangmurphy @Uroweb
    Image
    GIF
    32K032K
  • user avatar
    Michael Hofman
    @DrMHofman
    Aug 7, 2024
    Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer rdcu.be/dQg5y Congrats @RenuEapen for leading this work just published in @Nature Reviews Urology @declangmurphy @lewisjwau @lawrentschuk @gu_onc
    Image
    17K017K
  • user avatar
    Michael Hofman
    @DrMHofman
    Jun 5, 2022
    SUVmean > 10 on PSMA PET in the Vision trial had improved OS and PFS. It's extraordinary that we found the same cut-off in our ph2 @PeterMacCC study and @ANZUPtrials #TheraP study. **WE HAVE A NEW BIOMARKER** #ASCO22 @ASCO
    Image
    Image
  • user avatar
    Michael Hofman
    @DrMHofman
    Mar 17, 2022
    Introducing the new PRIMARY score for reporting PSMA PET: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer DIAGNOSIS. We feel this is MAJOR advance for interpretation of PSMA PET. jnm.snmjournals.org/content/early/… @drlouiseemmett @JournalofNucMed
    Image
    Image
  • user avatar
    Michael Hofman
    @DrMHofman
    Feb 17, 2022
    1/ Hot of the press: #TheraP Imaging Biomarkers presented @asco #GU21. PSMA PET is a PREDICTIVE biomarker: patients randomised to Lu-PSMA-617 with very high PSMA expression on PSMA PET had a 91% PSA RESPONSE RATE (PSA decline>50%). @ANZUPtrials @TrialsCentre
    Image
  • user avatar
    Michael Hofman
    @DrMHofman
    Apr 8, 2023
    Diagnostic Accuracy of PSMA PET/CT for Initial Staging of Intermediate to High-risk Prostate Cancer: Systematic Review and Meta-analysis "PSMA-PET should be used as a first-line approach for the initial staging of PCa." sciencedirect.com/science/articl… @EUplatinum @declangmurphy
    Image
    16K016K
  • user avatar
    Michael Hofman
    @DrMHofman
    Jul 14, 2024
    Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht nature.com/articles/s4158…
    Image
    Image
    Image
    Image
    user avatar
    Misha Beltran
    @mishabeltran
    Jul 9, 2024
    Check out our new review in @NatRevUrol on biologic determinants of PSMA expression, regulation, and heterogeneity in prostate cancer led by @mkbakht @DanaFarber_GU @PCF_Science Link to paper: rdcu.be/dM7GF nature.com/articles/s4158…
    29K029K
  • user avatar
    Michael Hofman
    @DrMHofman
    Mar 5, 2022
    THE HISTORY OF PSMA THERANOSTICS in this months @JournalofNucMed jnm.snmjournals.org/content/63/3/3… I think the 2022 headline will be FDA approval of Lu-177 PSMA-617 @PCF_Science @soulehoward1 @AndreaMiyahira @pros_tic
    Image
  • user avatar
    Michael Hofman
    @DrMHofman
    Feb 23, 2024
    New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !! jnm.snmjournals.org/content/early/… @DebiopharmNews @DrBenTran @JournalofNucMed @PeterMacRes
    Image
    Image
    Image
    Image
    11K011K
  • user avatar
    Michael Hofman
    @DrMHofman
    May 31, 2025
    Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 @ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma
    Image
    GIF
    14K014K
  • user avatar
    Michael Hofman
    @DrMHofman
    May 3, 2025
    Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in
    Image
    11K011K
Advertisement
Advertisement